New antibody shows promise against rare liver infection
NCT ID NCT05861674
First seen Oct 31, 2025 · Last updated Jun 10, 2026 · Updated 33 times
Summary
This study tested an experimental drug called HH-003 in 101 adults with chronic hepatitis delta, a serious liver infection. The drug is an antibody that targets the hepatitis B virus, which is needed for hepatitis delta to survive. The goal was to see if the treatment could lower virus levels and improve liver health, but it is not a cure and ongoing management is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS DELTA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Ditan Hospital Captial Medical University
Beijing, Beijing Municipality, 100015, China
Conditions
Explore the condition pages connected to this study.